BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 24759080)

  • 1. New management algorithms in multiple sclerosis.
    Sorensen PS
    Curr Opin Neurol; 2014 Jun; 27(3):246-59. PubMed ID: 24759080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on multiple sclerosis treatments.
    Bridel C; Lalive PH
    Swiss Med Wkly; 2014; 144():w14012. PubMed ID: 25247669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Update on current care guidelines: multiple sclerosis].
    Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral treatment for multiple sclerosis.
    Killestein J; Rudick RA; Polman CH
    Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current management of relapsing-remitting multiple sclerosis.
    Sedal L; Wilson IB; McDonald EA
    Intern Med J; 2014 Oct; 44(10):950-7. PubMed ID: 25302718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on disease-modifying treatments for multiple sclerosis.
    Carrithers MD
    Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Ingwersen J; Aktas O; Hartung HP
    Neurotherapeutics; 2016 Jan; 13(1):47-57. PubMed ID: 26701666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update on Current Care Guideline: Multiple sclerosis].
    Remes A; Airas L; Atula S; Färkkilä M; Hartikainen P; Koivisto K; Mäenpää E; Ruutiainen J; Sumelahti ML;
    Duodecim; 2015; 131(5):500-1. PubMed ID: 26237913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapies in relapsing-remitting multiple sclerosis.
    Marriott JJ; O'Connor PW
    Rev Recent Clin Trials; 2010 Sep; 5(3):179-88. PubMed ID: 20500147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
    Zhang X; Hay JW; Niu X
    CNS Drugs; 2015 Jan; 29(1):71-81. PubMed ID: 25326785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.
    Freedman MS
    Eur J Neurol; 2014 Mar; 21(3):377-87, e18-20. PubMed ID: 24237582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.